| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | August 19, 2025 |
| Accession Number: | 0001213900-25-076945 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)
Business combination transaction with Helix Acquisition Corp. II, a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, completed on August 11, 2025 Closed concurrent $261 million private investment in public equity ("PIPE"), led by Cormorant Combining approximately $120 million from the former Helix II trust account (reflecting a final redemption rate of approximately 39% which is the second lowest redemption rate for a biotech de-SPAC transaction since 2022) with the PIPE provides approximately $382 million in gross proceeds Net proceeds will be used to accelerate the development of BBOT's pipeline of clinical-stage RAS-targeted oncology drug candidat
Gross proceeds of approximately $120 million from trust account and approximately $261 million from PIPE financing to be available to the combined company at the closing2nd lowest redemption rate for a biotech de-SPAC transaction since 2022 BOSTON & SOUTH SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company sponsored by affiliates of Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that Hel
Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b
EFFECT - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)
SCHEDULE 13G - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)
SCHEDULE 13D/A - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)
SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)